RYMPHYSIA 500mg powder + solvent infusion solution medication leaflet

B02AB02 human alfa-1 proteinase inhibitor • Blood and blood forming organs | Antifibrinolytics | Proteinase inhibitors

Human alpha-1 proteinase inhibitor is used for the treatment of alpha-1 antitrypsin deficiency, a genetic condition that can lead to lung diseases such as emphysema. It works by protecting lung tissue from enzymatic degradation.

The medication is administered intravenously, as directed by a doctor. It is important to monitor the patient for adverse reactions during the infusion.

Side effects may include headache, fever, dizziness, or injection site reactions. In rare cases, severe allergic reactions may occur.

This medication is not recommended for patients with hypersensitivity to human plasma proteins or severe IgA deficiency.

General data about RYMPHYSIA 500mg

Substance: human alfa-1 proteinase inhibitor

Date of last drug list: 01-07-2022

Commercial code: W68873001

Concentration: 500mg

Pharmaceutical form: powder + solvent infusion solution

Quantity: 1

Product type: original

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: TAKEDA MANUFACTURING AUSTRIA AG - AUSTRIA

Holder: TAKEDA MANUFACTURING AUSTRIA AG - AUSTRIA

Number: 14494/2022/01

Shelf life: 24 months-after packaging for sale;after reconstitution-it is used immediately

Concentrations available for human alfa-1 proteinase inhibitor

1000mg, 500mg

Other substances similar to human alfa-1 proteinase inhibitor